It’s been an exciting past few years in the drug development pipeline for MS (among other diseases). As someone who studied pharmaceutical science in graduate school nearly 20 years ago, as I vaguely follow industry news, I (and others) had thought that new pathways of drug discovery had dried up. Or so the media was telling us.

Introducing the world of monoclonal antibodies. Without getting too techie, they’re designed to bind specifically to an item (or cell, in this case) which is the bad guy, thereby deactivating it. From my years-old lab experience, I can imagine that the R&D on these ain’t cheap… but they’ve proven effective for many conditions.

Several MS MAb drugs are in the pipeline right now, going through late stage clinical trials. They look very promising, including this one that I’ll be keeping an eye out for–better response than Rebif:

Best yet, most of these drugs are dosed through just a few intravenous infusions per year… which sounds great to someone like me, who injects myself 3 times per week.

The future looks bright!


No Responses Yet to “pipeline”

  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: